ƽ

ImmunoCult™ NK Cell Expansion Kit

Kit for the culture and expansion of human NK cells

ImmunoCult™ NK Cell Expansion Kit

Kit for the culture and expansion of human NK cells

Catalog #
(Select a product)
Kit for the culture and expansion of human NK cells
Request Pricing Request Pricing

Product Advantages


  • Robust expansion of NK cells with high yield and frequency

  • Feeder- and serum-free culture conditions

  • Expanded NK cells are functional with cytotoxic potential

What's Included

  • ImmunoCult™ NK Cell Base Medium, 500 mL (Catalog #100-0712)
  • ImmunoCult™ NK Cell Expansion Supplement, 5 mL (Catalog #100-0715)
  • ImmunoCult™ NK Cell Expansion Coating Material, 1.5 mL (Catalog #100-0714)
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

Overview

Consistently expand natural killer (NK) cells in serum-free conditions without the use of problematic feeder cells.

Use ImmunoCult™ NK Cell Expansion Kit to provide optimized culture conditions for expanding NK cells with high yields. This kit comprises ImmunoCult™ NK Cell Base Medium, ImmunoCult™ NK Cell Expansion Supplement, and ImmunoCult™ NK Cell Expansion Coating Material, providing you with a complete, easy-to-use culture system. After just 14 days in culture, cells can be harvested and used directly in your downstream applications.

This kit is compatible with many of our other upstream and downstream products. For example, you can use ⳧™ cell separation kits to isolate NK cells that can then be immediately expanded using ImmunoCult™ NK Cell Expansion Kit.
Subtype
Specialized Media
Cell Type
NK Cells
Species
Human
Application
Cell Culture, Expansion
Brand
ImmunoCult
Area of Interest
Cancer, Drug Discovery and Toxicity Testing, Immunology, Cell Therapy Development
Formulation Category
Animal Component-Free, Serum-Free, Xeno-Free

Data Figures

Protocol for the Expansion of Natural Killer (NK) Cells Using the ImmunoCult™ NK Cell Expansion Kit

Figure 1. ImmunoCult™ NK Cell Expansion Protocol

Human natural killer (NK) cells are isolated from blood or leukapheresis using ⳧™ selection. The NK cells are cultured in ImmunoCult™ NK Cell Expansion Medium, on plates coated with ImmunoCult™ NK Cell Expansion Coating Material. After 3 days, fresh medium is added to the culture. On day 7, and again on day 10 or 11, expanding NK cells are harvested and replated on freshly coated plates. Expanded NK cells were harvested on day 14 for use in downstream assays.

Cell Frequency, Fold Expansion, and Phenotyping of Natural Killer (NK) Cells Cultured Using the ImmunoCult™ NK Cell Expansion Kit

Figure 2. CD56+CD3− NK Cells Expand Over 14 Days in Feeder- and Serum-Free Culture Conditions

Isolated human CD56+CD3− NK cells were cultured using ImmunoCult™ NK Cell Expansion Kit for 14 days (Figure 1). Cells were harvested and analyzed for expression of characteristic NK cells markers, including CD56, CD3, CD16, CD94, KIR, NKG2D, NKp46, NKp30, and NKp44 by flow cytometry. Staining for killer cell immunoglobulin-like receptor (KIR) molecules was performed using two different antibody clones, HP-MA4 and 180704, which recognize distinct KIR molecules. Dead cells were excluded by light-scatter profile and DRAQ7™ staining. (A - H) Representative flow cytometry plots. (I) The average frequencies of viable CD56+CD3− and CD56+CD16+ NK cells on day 14 were 87 ± 1% and 75 ± 2%, respectively. The average fold expansion of CD56+CD3− cells was 89 ± 17. Results shown represent mean ± SEM (n = 34).

Cytotoxicity of Expanded Natural Killer (NK) Cells Co-Cultured with K562 Cells

Figure 3. Expanded NK Cells Are Functional, Killing K562 Cells in Co-Culture

Isolated CD56+CD3− NK cells were expanded as described in Figure 1. Expanded NK cells were co-cultured with Incucyte® Cytolight Rapid Dye-labeled K562 cells at 1:1 ratio of NK:K562 cells at 37°C for 4 hours. Incucyte® Caspase-3/7 Dye, a caspase-inducible dye, was added to the co-culture to detect caspase-induced apoptosis of the K562 cells. Images were obtained every hour using the Incucyte® imaging system and then analyzed to determine % killing (# apoptotic K562 cells ÷ # total labeled K562 cells). After 4 hours, an average of 48 ± 2.4% K562 cells were killed (n = 9). Data represent mean ± SEM.

Degranulation and Cytokine Production in Stimulated Natural Killer (NK) Cells Expanded Using the ImmunoCult™ NK Cell Expansion Kit

Figure 4. Expanded NK Cells Degranulate and Produce Cytokines After Stimulation

Isolated CD56+CD3− NK cells were expanded for 14 days (Figure 1). Expanded NK cells were left unstimulated (control) or were stimulated with either phorbol 12-myristate 13-acetate (PMA) and ionomycin or K562 cells at a ratio of 1:1 effector:target cells. CD107a antibody was added, and cultures were incubated at 37°C for 4 hours. After the first hour, Monensin and Brefeldin A were added. Cells were assessed for surface CD56, CD107a, and intracellular IFN-γ and TNF-α expression by flow cytometry. (A-C) Representative histograms of CD107a, IFN-γ, and TNF-α expression of unstimulated (grey filled), PMA and ionomycin-stimulated (orange), and K562-stimulated (purple) NK cell samples. (D) The average frequency of NK cells expressing surface CD107a, a marker of degranulation, was 23 ± 5% for the unstimulated control, 88 ± 5% after stimulation with PMA and ionomycin, and 74 ± 6% after stimulation with K562 cells. (E) The average frequency of NK cells expressing intracellular IFN-γ was 10 ± 2% for the unstimulated control, 75 ± 4% for cells stimulated with PMA and ionomycin, and 48 ± 4% for cells co-cultured with K562 cells. (F) The average frequency of NK cells expressing intracellular TNF-α was 6 ± 4% for the unstimulated control, 85 ± 1% cells stimulated with PMA and ionomycin, and 45 ± 4% for cells co-cultured with K562 cells. Data represent mean ± SEM (n = 6 - 13).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
100-0711
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0715
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0712
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0714
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0711
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0711
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0711
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0715
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0712
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0714
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (7)

Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells A. Calescibetta et al. PLOS One 2026 Mar

Abstract

Background: Lenalidomide is an immunomodulatory drug approved in the treatment of autoimmune disease, inflammation, and cancer. Its impact continues to grow due to its diverse spectrum of effects hampered only by toxicities and reduced efficacy. Therefore, development of strategies that enhance function while reducing drawbacks remains a prime goal. Objective and Hypothesis: The mechanisms of action of lenalidomide on the activity of natural killer cells (NK cells) remains understudied yet could be critical for the development of strategies to enhance its efficacy. These cells are critical drivers of anti-tumor immune responses which are often functionally suppressed in malignancies. NK cell and T cell survival and function is driven by the IL-2 family of cytokines (IL-2 or IL-15) and work has shown that lenalidomide potentially works by increasing the secretion of IL-2 by other lymphocytes, such as CD4+ T helper cells. Thus, we hypothesized that improving NK activity with IL-2 family of cytokines could lead to enhanced lenalidomide-induced responses of these cells. Results: We show that lenalidomide does not affect NK cell viability but reduces their proliferation through cell cycle arrest which could be overcome by exogenous addition of IL-2 family of cytokines. Moreover, lenalidomide induced the secretion of IL-2 on isolated NK cells although it also modulated NK receptor expression, such as NKp46, trough downregulation of PI3K/AKT pathway reduction. This was overcome by exogeneous addition of IL-2 family of cytokines increasing natural cytotoxicity, through higher perforin and granzyme expression. Mechanistically, this increased gene and protein expression occurred through the activation of STAT5 by lenalidomide which was also enhanced through the exogenous addition of IL-2 family of cytokines and modulation of IL-2R subunit changes. Conclusions: These data provide a rationale for the combination of lenalidomide with IL-2 family of cytokines to enhance the effectiveness of NK cells.
Rewiring melanoma cell fate: TRPM8 modulators trigger apoptosis and boost NK cell cytotoxicity C. Sorrentino et al. Cell Death & Disease 2026 Feb

Abstract

Metastatic melanoma is an aggressive malignancy with limited long-term treatment success due to therapeutic resistance and immune evasion. The transient receptor potential melastatin 8 (TRPM8) ion channel is overexpressed in melanoma but its role as therapeutic target remains unexplored. We investigated the anti-tumor effects of novel TRPM8 modulators in metastatic melanoma cells using viability assays, apoptosis markers, mitochondrial function analyses, reactive oxygen species (ROS) measurements and gene silencing. Their functional impact was further assessed in 3D melanoma organoids, clonogenic survival assays, and natural killer (NK) cell co-culture systems. TRPM8 is significantly overexpressed in metastatic melanoma, as compared with the normal counterparts. Its pharmacological inhibition with novel modulators selectively induces calcium-independent mitochondrial apoptosis characterized by ROS accumulation, mitochondrial membrane depolarization, cytochrome c release, and caspase-3 activation. This process involves activation of the ATM/p53 pathway and upregulation of pro-apoptotic proteins. Additionally, TRPM8 modulators increase expression of the NK cell-activating ligand ULBP1, enhancing melanoma susceptibility to NK-mediated cytotoxicity. Our study identifies TRPM8 as a promising biomarker in melanoma. Its targeting triggers mitochondrial cell death and simultaneously boosts NK cell recognition via ULBP1/NKG2D engagement. TRPM8 targeting in combination with immunotherapy might be, hence, further explored in clinical setting of advanced melanoma.
Attenuation of natural killer cell cytotoxicity by interaction between NKp30 of NK cells and dipeptidase 1 of colon cancer cells Kim et al. Scientific Reports 2025 Oct

Abstract

Natural killer (NK) cells play a crucial role in immune surveillance by recognizing and eliminating tumor cells. However, tumors employ various mechanisms to evade NK cell-mediated immunity. NKp30 is a potent activating receptor on NK cells, but its function can be inhibited by specific ligands secreted by cancer cells. Here, we identified dipeptidase 1 (DPEP1) as a novel ligand for NKp30 in KM12C colon cancer cells, using co-immunoprecipitation, confocal microscopy, and flow cytometry. We examined how the DPEP1–NKp30 interaction affects NK cell activity and found that NK cytotoxicity increased in KM12C cells with DPEP1 knockdown but was significantly reduced in HCT116 cells overexpressing DPEP1. We further demonstrated that DPEP1 is secreted via extracellular vesicles and that its interaction with NKp30 suppressed the expression and secretion of perforin 1, granzyme B, CD107a, and interferon-γ in NK92 cells. In a xenograft mouse model treated with NK92 cells, tumors derived from HCT116/DPEP1 cells were significantly larger than those from HCT116/mock cells. Using peripheral blood-derived human NK cells, we confirmed that DPEP1 inhibited both cytotoxicity and granzyme B secretion. These findings suggest that disrupting the DPEP1–NKp30 interaction may enhance NK cell-mediated cytotoxicity and represent a novel therapeutic strategy for cancer immunotherapy. The online version contains supplementary material available at 10.1038/s41598-025-18475-z.